Trial Profile
Safety and Efficacy of Baricitinib for COVID-19
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 09 Mar 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 pneumonia; COVID-19 respiratory infection
- Focus Adverse reactions
- 03 Mar 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as study could not make FDA required changes.
- 08 Feb 2021 Planned initiation date changed from 1 Nov 2020 to 1 Mar 2021.
- 24 Aug 2020 Planned End Date changed from 1 Oct 2020 to 1 Oct 2021.